Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR).

Trial Profile

Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2009

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms VIVIR
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 20 Nov 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Planned end date changed from 1 May 2009 to 1 Aug 2008 as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Actual patient number (14) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top